| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers IB Hilton, AM D'ippolito, CM Vockley, PI Thakore, GE Crawford, TE Reddy, ... Nature biotechnology 33 (5), 510-517, 2015 | 2200 | 2015 |
| Editing the epigenome: technologies for programmable transcription and epigenetic modulation PI Thakore, JB Black, IB Hilton, CA Gersbach Nature methods 13 (2), 127-137, 2016 | 523 | 2016 |
| CRISPR–Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome TS Klann, JB Black, M Chellappan, A Safi, L Song, IB Hilton, GE Crawford, ... Nature biotechnology 35 (6), 561-568, 2017 | 488 | 2017 |
| Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector AM Kabadi, DG Ousterout, IB Hilton, CA Gersbach Nucleic acids research 42 (19), e147-e147, 2014 | 462 | 2014 |
| Engineering the next generation of cell-based therapeutics CJ Bashor, IB Hilton, H Bandukwala, DM Smith, O Veiseh Nature Reviews Drug Discovery 21 (9), 655-675, 2022 | 253 | 2022 |
| RNA-guided gene editing and gene regulation CA Gersbach, IB Hilton, P Perez-Pinera, AM Kabadi, PI Thakore, ... US Patent 10,704,060, 2020 | 140 | 2020 |
| Enabling functional genomics with genome engineering IB Hilton, CA Gersbach Genome research 25 (10), 1442-1455, 2015 | 137 | 2015 |
| Transgenic mice for in vivo epigenome editing with CRISPR-based systems MP Gemberling, K Siklenka, E Rodriguez, KR Tonn-Eisinger, A Barrera, ... Nature methods 18 (8), 965-974, 2021 | 101 | 2021 |
| The sound of silence: Transgene silencing in mammalian cell engineering A Cabrera, HI Edelstein, F Glykofrydis, KS Love, S Palacios, J Tycko, ... Cell Systems 13 (12), 950-973, 2022 | 92 | 2022 |
| Single C-to-T substitution using engineered APOBEC3G-nCas9 base editors with minimum genome-and transcriptome-wide off-target effects S Lee, N Ding, Y Sun, T Yuan, J Li, Q Yuan, L Liu, J Yang, Q Wang, ... Science advances 6 (29), eaba1773, 2020 | 89 | 2020 |
| mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis D Roy, SH Sin, A Lucas, R Venkataramanan, L Wang, A Eason, ... Cancer research 73 (7), 2235-2246, 2013 | 85 | 2013 |
| CRISPR/Cas-based epigenome editing: advances, applications, and clinical utility JH Goell, IB Hilton Trends in Biotechnology 39 (7), 678-691, 2021 | 83 | 2021 |
| Distinct p53, p53: LANA, and LANA complexes in Kaposi's sarcoma-associated herpesvirus lymphomas W Chen, IB Hilton, MR Staudt, CE Burd, DP Dittmer Journal of virology 84 (8), 3898-3908, 2010 | 83 | 2010 |
| Programmable human histone phosphorylation and gene activation using a CRISPR/Cas9-based chromatin kinase J Li, B Mahata, M Escobar, J Goell, K Wang, P Khemka, IB Hilton Nature Communications 12 (1), 896, 2021 | 64 | 2021 |
| The open chromatin landscape of Kaposi's sarcoma-associated herpesvirus IB Hilton, JM Simon, JD Lieb, IJ Davis, B Damania, DP Dittmer Journal of virology 87 (21), 11831-11842, 2013 | 50 | 2013 |
| Temporal analysis suggests a reciprocal relationship between 3D chromatin structure and transcription KSM Reed, ES Davis, ML Bond, A Cabrera, E Thulson, IY Quiroga, ... Cell reports 41 (5), 2022 | 38 | 2022 |
| RNA-guided gene editing and gene regulation CA Gersbach, IB Hilton, P Perez-Pinera, AM Kabadi, PI Thakore, ... US Patent 10,745,714, 2020 | 30 | 2020 |
| Systematic comparison of CRISPR-based transcriptional activators uncovers gene-regulatory features of enhancer–promoter interactions K Wang, M Escobar, J Li, B Mahata, J Goell, S Shah, M Cluck, IB Hilton Nucleic Acids Research 50 (14), 7842-7855, 2022 | 28 | 2022 |
| Reversing post-infectious epigenetic-mediated immune suppression Abhimanyu, CO Ontiveros, RS Guerra-Resendez, T Nishiguchi, M Ladki, ... Frontiers in immunology 12, 688132, 2021 | 26 | 2021 |
| Compact engineered human mechanosensitive transactivation modules enable potent and versatile synthetic transcriptional control B Mahata, A Cabrera, DA Brenner, RS Guerra-Resendez, J Li, J Goell, ... Nature Methods 20 (11), 1716-1728, 2023 | 23* | 2023 |
Charles GersbachProfessor of Biomedical Engineering, Duke UniversityПодтвержден адрес электронной почты в домене duke.edu
